Celldex Therapeutics
CLDX
102 hedge funds and large institutions have $27.4M invested in Celldex Therapeutics in 2018 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 21 increasing their positions, 37 reducing their positions, and 48 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.97% less ownership
Funds ownership: 3.5% → 2.53% (-0.97%)
22% less funds holding
Funds holding: 131 → 102 (-29)
43% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 37
60% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 48
66% less call options, than puts
Call options by funds: $25K | Put options by funds: $74K
84% less capital invested
Capital invested by funds: $172M → $27.4M (-$145M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$3.62M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.64M |
| 3 |
Goldman Sachs
New York
|
+$1.37M |
| 4 |
Two Sigma Investments
New York
|
+$1.2M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$816K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$17.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.9M |
| 3 |
BlackRock
New York
|
-$5.81M |
| 4 |
TA
Teachers Advisors
New York
|
-$2.35M |
| 5 |
State Street
Boston,
Massachusetts
|
-$1.88M |
CLDX Hedge Fund Activity: Q2 2018 in Review
102 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q2 2018, worth a combined $27.4M — down 84% from $172M a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of CLDX and 19 opened new positions — a net loss of 29 holders — while 37 trimmed existing stakes and 21 added.
The largest buyer was Renaissance Technologies, adding an estimated $3.62M. The largest seller was Ameriprise, exiting entirely with an estimated $17.9M sold.
- 102 institutional investors held Celldex Therapeutics (CLDX) as of Q2 2018, down from 131 in Q1 2018.
- Funds reported $27.4M of Celldex Therapeutics stock for Q2 2018, down 84% quarter-over-quarter.
- 19 funds opened new Celldex Therapeutics positions in Q2 2018 and 48 closed out, a net change of -29 holders.
- The largest Celldex Therapeutics buyer in Q2 2018 was Renaissance Technologies, an estimated $3.62M added.
- The largest Celldex Therapeutics seller in Q2 2018 was Ameriprise, an estimated $17.9M sold.
Based on aggregated 13F filings for Q2 2018.